AI in Cardiology Through the use of Medical Devices
By Sumona Bose
February 7, 2024
Introduction
Wearable devices, such as smartphones, smart bands, and smartwatches, are now being used to detect Atrial fibrillation (AF), offering non-invasive and instantaneous access to patients. Moreover, voice technology, through voice assistants like Amazon’s Alexa or Google Assistant, is emerging as a valuable tool for remote monitoring and the provision of medical services in cardiology. These advancements in AI-driven clinical decision making with medical devices are transforming the way cardiovascular diseases are diagnosed and managed. AI in cardiology and medical devices have pioneered how personalised our healthcare can be.
Figure 1: Overview of the role of AI in cardiovascular medicine. Abbreviations: EHRs, electronic health records; CMR, cardiac magnetic resonance; CT, computed tomography; IoT, internet of things; SPECT, single photon-emission computerised tomography.
Wearable Devices for AF Detection
AF detection can be challenging due to the limitations of current diagnostic methods. However, advancements in technology have paved the way for the use of wearable devices in detecting AF. These devices, such as smartphones, smart bands, smartwatches, earlobe sensors, and handheld electrocardiogram devices, offer non-invasive and instantaneous access to patients.
The Apple Watch and AliveCor are notable examples of wearable devices that enable uninterrupted monitoring and individual analysis of electrocardiogram (ECG) signals. The KardiaBand from AliveCor, a smartphone application based on machine learning (ML), has been developed for the recognition of AF from an ECG. In a randomized controlled trial (RCT) of AF screening, the AliveCor Kardia monitor connected to a WiFi-enabled iPod successfully detected AF in ambulatory patients aged 65 and above at high risk of stroke. This screening method proved to be more effective than routine monitoring over a 12-month period.
Smartphone Utilization in Identifying Subclinical AF
The Apple Heart Study demonstrated the effectiveness of smartphones in identifying patients with subclinical paroxysmal AF. With data from 420,000 participants, the study detected irregular pulses in 0.5% of patients, 34% of whom were diagnosed with AF confirmed by ECG. Participants who received notifications about their irregular pulse had a higher likelihood of commencing anticoagulant or antiplatelet treatment. A significant number of patients diagnosed with AF underwent further interventions such as cardioversion, implantable loop recorder placement, anti-arrhythmic medication initiation, and ablation.
Figure 2: Demonstration of a Convolutional Neural Network (CNN) architecture. A CNN is composed of several blocks which include convolutional layers, pooling layers, and fully connected layers.
Voice Technology for Remote Monitoring and Medical Services
Voice technology, through voice assistants like Amazon’s Alexa or Google Assistant, has gained popularity for mainstream use. These advanced software architectures, based on neural network techniques, enable speech recognition and generate human-like responses. Voice assistants are now being utilized as emerging tools for remote monitoring and the provision of medical services.
In the field of cardiology, voice applications have proven to be valuable. For instance, the Mayo Clinic First Aid skill provides medical guidelines, including cardio-pulmonary resuscitation instructions. The CardioCube voice application facilitates paperless medical history taking in outpatient cardiology clinics, generating accurate reports.
Figure 3: FDA approved AI/ML based medical technologies/software.
Conclusion
The integration of AI into cardiology through medical devices has developed the detection and management of AF. Wearable devices, such as smartphones and smartwatches, offer non-invasive and instantaneous access to patients, allowing for continuous monitoring and analysis of electrocardiogram (ECG) signals. Voice technology has emerged as a valuable tool for remote monitoring and the provision of medical services in the field of cardiology.
🌟 Ready for a breakthrough in diabetes management?
Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.
Dive into the details of this exciting development and what it means for the future of diabetes care!
🌟 Are we overlooking environmental risks in pediatric cancer?
Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.
Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.
💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?
A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.
Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
